相关实验视频

Updated: Jul 2, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

SLC20A1是一种潜在的预后和治疗反应预测生物标志物,用于头部和部状细胞癌

Xiajing Qian¹, Ming Jin¹, Yanping Bei¹

¹Department of Radiation Oncology, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.

|February 27, 2024

概括

高SLC20A1表达与头部和部状细胞癌 (HNSCC) 的预后不佳有关. 这一发现表明SLC20A1可能成为HNSCC患者的关键预后生物标志物和治疗指标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

溶性载体家族20成员1 (SLC20A1) 是一种已知的癌症生物标志物,但其在头部和部状细胞癌 (HNSCC) 中的预测作用仍未得到充分研究.
了解SLC20A1在HNSCC中的功能对于开发新的诊断和治疗策略至关重要.

研究的目的:

研究SLC20A1在HNSCC中的预后意义.
探索SLC20A1表达与临床特征,患者存活率和HNSCC中的生物学途径之间的关联.

主要方法:

在HNSCC组织中使用TCGA,qRT-PCR和Western blot分析SLC20A1表达 (mRNA和蛋白质).
通过Transwell,伤口愈合和殖民地形成试验评估细胞行为 (入侵,迁移,增殖).
使用GO,KEGG,GSEA和TIMER/CIBERSORT数据库探索相关的生物途径和免疫微环境.

主要成果:

与正常组织相比,HNSCC组织中的SLC20A1mRNA和蛋白质表达显著增加.
高SLC20A1表达与晚期T阶段相关,增加了风险得分,并减少了HNSCC患者的整体存活率.
SLC20A1成为HNSCC预后的独立预测因素,除了阶段和年龄之外.

结论:

在HNSCC中SLC20A1的过度表达与细胞入侵,迁移和增殖的增加有关,这表明预后不佳.
在HNSCC中,SLC20A1作为潜在的预后生物标志物和治疗反应的预测指标.

关键词:

在 SLC20A1 中.在TCGA中,TCGA就是TCGA.癌症癌症癌症癌症癌症预后预后预后状细胞癌的癌症.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...